

REFERENCES

1. Intragumtornchai T, Wannakraij P, Chaimongkol B et al. Non-Hodgkin's lymphomas in Thailand: a retrospective pathologic and clinical analysis of 1,391 cases. *Cancer* 1996 ; 78: 1813-9.
2. Sullivan KA. Classification, pathogenesis and etiology of neoplastic diseases of the hematopoietic system. In *Wintrobe's Clinical Hematology*. Lee GR, Bithell TC, Forester J, eds: Lea and Febiger. Philadelphia, 1990, p 1739.
3. The Non-Hodgkin's Lymphoma pathologic Classification Project. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas : summary and description of a working formulation for clinical usage. *Cancer* 1982 ; 49 : 2112-35.
4. Armitage JO. Treatment of non-Hodgkin's lymphoma. *N Engl J Med* 1993; 328 : 1023-30.
5. Shipp MA, Harrington DP, Anderson JR et al. A predictive model for aggressive NHL : The International Non-Hodgkin's Lymphoma Prognostic Factors Project. *N Engl J Med* 1993 ; 329 : 987-94.
6. Meyer RM, Hryniuk WM, Goodyear MDE. The role of dose intensity in determining outcome in intermediate grade non-Hodgkin's lymphoma. *J Clin Oncol* 1991 ; 9 : 339-47.
7. Hoskins PJ, Ng V, Spinelli JJ. et al. Prognostic variables in patients with diffuse large cell lymphoma treated with MACOP-B. *J Clin Oncol* 1991 ; 9 : 220-6.
8. Frei E, Canellos GP. Dose: A critical factor in cancer chemotherapy. *Am J Med* 1980 ; 69 : 585-94.
9. Gehan EA. Dose-response relationships in clinical oncology. *Cancer* 1984; 54 : 1204-7.
10. Philip T, Armitage JO, Spitzer G. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate grade or high grade non-Hodgkin's lymphoma. *N Engl J Med* 1987 ; 316 : 1493-8.

11. Gribben JG, Goldstone AH, Linch DC. et al. Effectiveness of high dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphomas who are still responsive to conventional-dose therapy. *J Clin Oncol* 1989 ; 7 : 1621-9.
12. Takvorian T, Canellos GP, Ritz J. et al. Prolonged disease free survival after bone marrow transplantation in patients with NHL with a poor prognosis. *N Engl J Med* 1987 ; 316 : 1499-1505.
13. Armitage JO, Weisenburger DD, Hutchins M. et al. Chemotherapy for diffuse large cell lymphoma- rapidly responding patients have more durable remission. *J Clin Oncol* 1986 ; 4 : 160-4.
14. Colombat P, Gorin NC, Lemonnier MP, et al. The role of autologous bone marrow transplantation in 46 adults patients with non-Hodgkin's lymphoma. *J Clin Oncol* 1990 ; 8 : 630-7.
15. Nademanee A, Schmidt GM, O'Donnell MR. et al. High-dose chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adults patients with poor-risk aggressive lymphoma : A pilot study. *Blood* 1992 ; 80 : 1130-4.
16. Philip T, Hartmann O, Biron P. et al. High dose therapy and autologous bone marrow transplantation in partial remission after first-line induction therapy for diffuse non-Hodgkin's lymphoma. *J Clin Oncol* 1988 ; 6 : 1118-24.
17. Brugger W, Gramatzki M, Kollmannsberger C. et al. Early high dose chemotherapy with autologous peripheral blood progenitor cell (PBPC) transplantation in patients with high risk aggressive non-Hodgkin's lymphoma. *Blood* 1994 ; 84 (Suppl 1) : Abstract 923.
18. Korbling M, Juttner C, Henon P, Kessinger A. Autologous blood stem cell versus bone marrow transplantation. *Bone Marrow Transplant* 1992;10 (Suppl 1) : 144-8.

19. Sheridan WP, Begley CG, Juttner CA. et al. Effect of peripheral blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. *Lancet* 1992 ; 339 : 640-4.
20. Pettengell R, Morgenstern GR, Woll PJ. et al. Peripheral blood progenitor cell transplantation in lymphoma and leukemia using a single apheresis. *Blood* 1993 ; 82 : 3770-7.
21. Kessinger A, Vose JM, Bierman PJ, Bishop MR, Armitage JO. Peripheral blood stem cell transplantation in malignant lymphomas. *Hematol Oncol Annals* 1994 ; 2 : 47-52.
22. Gianni AM, Bregni M, Siena S. et al. High-dose therapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. *N Engl J Med* 1997 ; 336 : 1290-7.
23. Billroth T. Multiple lymphoma: Erfolgreich Behandlung mit Arsenik. *Wien Med Wochenschr* 1871 ; 21 : 1066.
24. Virchow R. Die Krankhaften Geschwulste. Dreissig Vorlesungen gehalten wahrend des Wintersemesters 1862-1863 an der Universitat zu Berlin. Vol 2. A Hirschwald, Berlin, 1864-5.
25. Brill NF, Baehr G, Rosenthal N. Generalized giant lymph node hyperplasia of lymph nodes and spleen. A hitherto undescribed type. *JAMA* 1925 : 84 : 668.
26. Rappaport H, Winter WJ, Hicks EB. Follicular lymphoma. A reexamination of its position in the scheme of malignant lymphoma, based on a survey of 253 cases. *Cancer* 1956 ; 9 : 792-821.
27. Lennert K, Mohri N, Stein H. et al. Malignant Lymphomas Other Than Hodgkin's Disease: Histology, Cytology, Ultrastructure, Immunology. Springer-Verlag, New York, 1978.
28. Lukes RJ, Collins RD. Immunologic characterization of human malignant lymphomas. *Cancer* 1974 ; 34 : 1488-503.
29. DeVita VT, Canellos GP, Chabner K. et al. Advanced diffuse histiocytic lymphoma, a potentially curable disease: results with combination chemotherapy. *Lancet* 1975 ; 1 : 248-50.

30. McKelvey EM, Gottlieb JA, Wilson HE. et al. Hydroxydaunomycin (Adriamycin) combination chemotherapy in malignant lymphoma. *Cancer* 1976 ; 38 : 1484-93.
31. Laurence J, Coleman M, Allen S. et al. Combination chemotherapy of advanced diffuse hidtiocytic lymphoma with the six-drug COP-BLAM regimen. *Ann Intern Med* 1982 ; 97 : 190-5.
32. Klimo P, Connors JM. MACOP-B chemotherapy for the treatment of diffuse large-cell lymphoma. *Ann Int Med* 1985 ; 102 : 596-602.
33. Fisher RI, DeVita VT Jr, Hubbard SM, et al. Randomized trial of ProMACE-MOPP vs. ProMACE-CytaBOM in previously untreated, advanced stage, diffuse aggressive lymphomas. *Proc Am Soc Clin Oncol* 1984 ; 3 : 242.
34. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. *N Engl J Med* 1993 ; 328 : 1002-6.
35. Canellos GP, Nadler L, Takvorian T. Autologous bone marrow transplantation in the treatment of malignant lymphoma and Hodgkin's disease. *Semin Oncol* 1988 ; 25 (suppl 2) : 58-65.
36. Hartge P, Devesa SS, Fraumeni JFJ. Hodgkin's and non-Hodgkin's lymphomas. In Doll R, Fraumeni R, Muir C (eds): *Trends in Cancer Incidence and Mortality Cancer Surveys*. Cold Spring, Cold Spring Harbor Laboratory Press, 1994, pp 423-53.
37. Ries LAG, Miller BA, Hankey BF. et al (eds): *SEER Cancer Statistics Review, 1973-1991: Tables and Graphs*, National Cancer Institute. NIH Publication No. 94-2789, Bethesda, MD, US Department of Health and Human Service, 1994.
38. Vatanasapt V, Martin H, Sripang K, Chidavijak K, Sontipong S, Sriarnporn S, Parkin DM (eds). *Cancer in Thailand 1988-91*. IARC Technical Report No. 6, Lyon, 1993.
39. Levine AM, Shibata D, Sullivan HJ. et al. Epidemiological and biological study of acquired immunodeficiency syndrome-related lymphoma

- in the County of Los Angeles: preliminary results. *Cancer Res* 1992; 52 : 5482 S-84S.
40. Ott G, Ott NM, Feller AC, Seidl S, Muller-Hermelink HK. Prevalence of Epstein-Barr virus DNA in different T-cell entities in a European population. *Int J Cancer* 1992 ; 51 : 562-7.
 41. CDC: Revision of the acse definition of acquired immunodeficiency. *MMWR Morb Wkly Rep* 1985 ; 34 : 373.
 42. Beral V, Peterman T, Berkelman R, Jaffe H. AIDS-associated non-Hodgkin's lymphoma. *Lancet* 1991 ; 337 : 805-9.
 43. Pluda JM, Venzon DJ, Tosato G. et al. Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy. *J Clin Oncol* 1993 ; 11 : 1099-1107.
 44. MacMahon EMF, Glass JD, Hayward SD. et al. Epstein-Barr virus in AIDS-related primary central nervous system lymphoma. *Lancet* 1991 ; 338 : 969-73.
 45. Uchiyama T, Sagawa K, Takatsuki K. et al. Adult T-cell leukemia : Clinical and hematologic features of 16 cases. *Blood* 1977 ; 50 : 481-92.
 46. Kajiyama W, Kashiwagi S, Nomura H. et al. Seroepidemiologic study of antibody to adult T-cell leukemia virus in Okinawa, Japan. *Am J Epidemiol* 1986 ; 123 : 41-7.
 47. Murphy EL, Hanchard B, Figueroa JP. et al. Modelling the risk of adult T-cell leukemia/lymphoma type I. *Int J Cancer* 1989 ; 43 : 250-3.
 48. Okochi K, Sato H, Hinuma Y. A retrospective study on transmission of adult T-cell leukemia virus by blood transfusion: seroconversion in recipients. *Vox Sang* 1984 ; 46 : 245-53.
 49. Jarrett RF, Gledhill S, Qureshi F. et al. Identification of human herpes 6-specific sequences in two patients with non-Hodgkin's lymphoma. *Leukemia* 1988 ; 2 : 496-502.
 50. Josephs SF, Buchbinder A, Streicher HZ. et al. Detection of human B-lymphotropic virus (human herpesvirus 6) sequences in B-cell lymphomas tissues of three patients. *Leukemia* 1988 ; 2 : 132-5.

51. Green MH. Non-Hodgkin's lymphoma and mycosis fungoides. In Schottenfeld D, Fraumeni JF Jr (eds): *Cancer Epidemiology and Prevention*. Philadelphia, WB Saunders, 1982, pp 754-78.
52. Linos A, Blair A, Gibson RW, et al. Leukemia and non-Hodgkin's lymphoma and residual proximity to industrial plants. *Arch Environ Health* 1991 ; 46 : 70-4.
53. Pasqualetti P, Casale R, Colantonio D, Collacciani A. Occupational risk for hematological malignancies. *Am J Hematol* 1991 ; 38 : 147-9.
54. Cantor KP, Blair A, Everett G. et al. Pesticides and other agricultural risk factors for non-Hodgkin's lymphoma among men in Iowa and Minnesota. *Cancer Res* 1992 ; 52 : 2447-55.
55. Scherr PA, Hutchison BB, Neiman RS. Non-Hodgkin's lymphoma and occupational exposure. *Cancer Res* 1992 ; 52 : 5503S-9S.
56. Blair A, Linos A, Stewart PA. et al. Comments on occupational and environmental factors in the origin of non-Hodgkin's lymphoma. *Cancer Res* 1992 ; 52 : 5501S-2S.
57. Hardell L. Malignant lymphoma of histiocytic type and exposure to phenoxyacetic acids or chlorophenols. *Lancet* 1979 ; 1 : 55-6.
58. Zahm SH, Blair A. Pesticides and non-Hodgkin's lymphoma. *Cancer Res* 1992 ; 52 : 5485S-8S.
59. Hardell L, Eriksson M, Lenner P, Lungren E. Malignant lymphoma and exposure to chemicals, especially organic solvents, chlorophenols, and phenoxy acids: a case-control study. *Br J Cancer* 1981 ; 43 : 169-76.
60. Hoar SK, Blair A, Holmes FF, et al. Agricultural herbicide use and risk of lymphoma and soft tissue sarcoma. *JAMA* 1986 ; 256 : 1141-7.
61. Zahm SH, Weisenburger DD, Babbitt PA, et al. A case-control study of non-Hodgkin's lymphoma and the herbicide 2,4-dichlorophenoxyacetic acid (2,4-D) in eastern Nebraska. *Epidemiology* 1990 ; 1 : 349-56.
62. *Veterans and Agent Orange: health effects of herbicides used in Vietnam*. Washington, DC, National Academy of Science, 1994.

63. Ames BN, Kammen HO, Yamasaki E. Hair dyes are mutagenic: identification of a variety of mutagenic gradients. Proc Natl Acad Sci USA 1975 ; 72 : 2423-7.
64. Cantor KP, Blair A, Everett G. et al. Hair dye use and risk of leukemia and lymphoma. Am J Public Health 1988 ; 78 : 570-1.
65. Zahm SH, Weisenburger DD, Babbitt PA. et al. Use of hair coloring products and the risk of lymphomas, multiple myeloma, and chronic lymphocytic leukemia. Am J Public Health 1992 ; 82 : 990-7.
66. Thun MJ, Altekruse SF, Namboodiri MM. et al. Hair dye use and risk of fatal cancers in U.S. women. J Natl Cancer Inst 1994 ; 86 : 210-5.
67. Boice JJ. Radiation and non-Hodgkin's lymphoma. Cancer Res 1992 ; 52: 5489S-91S.
68. Filipovich AH, Mathur A, Kamat D. et al. Primary immunodeficiencies: genetic risk factors for lymphoma. Cancer Res 1992 ; 52 : 5465S-7S.
69. Penn I, Starzl J. Malignant tumors arising *de novo* in immunosuppressed organ transplant recipients. Transplantation 1972 ; 11 : 407-17.
70. Hoover R, Fraumeni JF. Risk of cancer in renal transplant patients. Lancet 1973 ; 2 : 55-7.
71. Anderson JL, Bieber CP, Fowles RE. et al. Idiopathic cardiomyopathy, age, and suppressor-cell dysfunction as risk determinants of lymphoma after cardiac transplantation. Lancet 1978 ; 2 : 1174-7.
72. Kinlen L. Immunosuppressive therapy and acquired immunological disorders. Cancer Res 1992 ; 52 : 5474S-6S.
73. Hoover R, Mason TJ, McKay FW. et al. Geographic patterns of cancer mortality in the U.S. In Jr FJ (eds): Persons at High Risk of Cancer. New York, Academy Press, 1975, pp 343-60.
74. Offit K, Wong G, Filippa DA. et al. Cytogenetic analysis of 434 consecutive ascertained specimens of non-Hodgkin's lymphoma: clinical correlation. Blood 1991 ; 7 : 1508-15.

75. Offit K, Jhanwar S, Ebrahim SAD. et al. t(3;22)(q27;q11): a novel translocation associated with diffuse non-Hodgkin's lymphoma. *Blood* 1989 ; 74 : 1876-83.
76. Ye BH, Lista F, Lo Coco F. et al. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large cell lymphoma. *Science* 1993 ; 262 : 747-50.
77. Ye BH, Lista F, Lo Coco F. et al. Rearrangements of the BCL-6 gene in diffuse large cell non-Hodgkin's lymphoma. *Blood* 1994 ; 83 : 1757-9.
78. Rosenberg UB, Schroder C, Preiss A. et al. Structural homology of the product of the *Drosophila* Kruppel gene with *Xenopus* transcription factor IIIA. *Nature* 1986 ; 319 : 336.
79. Chang C-C, Ye BH, Chaganti RSK, Dalla-Favera R. BCL-6, a POZ/Zinc-finger protein, is a sequence-specific transcriptional repressor. *Proc Natl Acad Sci USA* 1996 ; 93 : 6947-42.
80. Ye BH, Chaganti RSK, Chang C-C. et al. Chromosomal translocation cause deregulated BCL-6 expression by promoter substitution in B-cell lymphoma. *EMBO J* 1995 ; 14 : 6209-17.
81. Dallery E, Galliegue-Zouitina S, Collyn-d'Hooghe M. et al. TTF, a gene encoding a novel small G protein, fuses to the lymphoma associated LAZ3 gene by t(3,4) chromosomal translocation. *Oncogene* 1995 ; 10 : 2171-8.
82. Galliegue-Zouitina S, Quief S, Hildebrand M-P. et al. Fusion of the LAZ3/BCL6 and BOB1/OBF1 genes by t(3;11)(q27;q23) chromosomal translocation. *C.R. Acad Sci Paris* 1995 ; 318 : 1125-31.
83. Yunis JJ, Oken NM, Kaplan ME. et al. Distinctive chromosome abnormalities in histologic subtypes of non-Hodgkin's lymphomas. *N Engl J Med* 1982 ; 307 : 1231.
84. Clearly ML, Sklar J. Nucleotide sequence of at (14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint

- cluster region near a transcriptionally active locus on chromosome 18. Proc Natl Acad Sci USA 1985 ; 82 : 7439-43.
85. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of *bcl-2*, the gene involved in follicular lymphoma. Proc Natl Acad Sci USA 1986 ; 83 : 5214-8.
86. Sentman CL, Shutter JR, Hockenbery D. et al. *bcl-2* inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 1991 ; 67: 879-88.
87. Strasser A, Harris AW, Cory S. et al. *bcl-2* transgene inhibits T-cell death and perturbs thymic self-censorship. Cell 1991 ; 67 : 889-99.
88. Li Y-S, Hayakawa K, Hardy RR. The regulated expression of B lineage associated genes during B-cell differentiation in bone marrow and fetal liver. J Exp Med 1993 ; 178 : 951-60.
89. Merino R, Ding L, Veis DJ. et al. Developmental regulation of the Bcl-2 protein and susceptibility to cell death in B lymphocytes. Eur Mol Bio Org J 1994 ; 13 : 683-91.
90. Hockenbery DM, Zutter M, Hickey W. et al. BCL-2 protein is topographically restricted in tissues characterized by apoptotic cell death. Proc Natl Acad Sci USA 1991 ; 88 : 6961-5.
91. Chleq-Deschamps CM, LeBrun DP, Huie P. et al. Topological dissociation of BCL-2 messenger RNA and protein expression in human lymphoid tissues. Blood 1993 ; 81 : 293-8.
92. Taub R, Kirsch I, Morton C. et al. Translocation of the *c-myc* gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells. Proc Natl Acad Sci USA 1982; 79:7837-41.
93. Dalla-Favera R, Bregni M, Erikson J. et al. Human *c-myc* oncogene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci USA 1982 ; 79 : 7824-7.
94. Sandlund JT, Necker LM, Schneller HE. et al. Theophylline induced differentiation provides direct evidence for the deregulation of the *c-myc* in Burkitt's lymphoma and suggests participation of

- immunoglobulin enhancer sequences. *Cancer Res* 1992 ; 53 : 127-32.
95. Lenoir GM, Bornkamm GW. Burkitt's lymphoma, a human cancer model for the study of the multistep development of cancer: proposal for a new scenario. *Adv Virol Oncol* 1987 ; 7 : 173.
96. Gaidano G, Ballerini P, Gong JZ. et al. p53 mutation in human lymphoid malignancies : association with Burkitt lymphoma and chronic lymphocytic leukemia. *Proc Natl Acad Sci USA* 1991 ; 88 : 5413-7.
97. Mathe G, Rappaport H, O'Connor GT. et al. Histological and cytological typing of neoplastic diseases of hematopoietic and lymphoid tissues. In: WHO International Histological Classification of Tumors. No. 14. World Health Organization, Geneva, 1976.
98. Gerald-Merchant R, Hamlin I, Lennert K. et al. Classification of non-Hodgkin's lymphomas. *Lancet* 1974 ; 2 : 406-8.
99. Harris NL, Jaffe ES, Stein H. et al. A revised European-American classification of lymphoid neoplasms; a proposal from the International Lymphoma Study Group. *Blood* 1994 ; 84 : 1361-92.
100. Kadin ME, Berard CW, Nanba K, Wakasa H. Lymphoproliferative diseases in Japan and Western countries. *Hum Pathol* 1983 ; 14 : 745-72.
101. Su U, Shih LY, Kadin ME, Dun P, Hsu SM. Pathologic and immunologic characterization of malignant lymphoma in Taiwan. *Am J Clin Pathol* 1985 ; 84 : 715-23.
102. Kim CW, Kim I, Ko YH. et al. Clinicopathologic and immunophenotypic study of non-Hodgkin's lymphoma in Korea. *J Korean Med Sci* 1992; 7 : 193-8.
103. Harrington DS, Ye Y, Weisenburger DD. et al. Malignant lymphoma in Nebraska and Guangzhou. *Hum Pathol* 1987 ; 18 : 924-8.
104. Garg A, Dawar R, Agarwal V, Rustagi RK, Kochupillai V. Non-Hodgkin's lymphoma in Northern India: a retrospective analysis of 238 cases. *Cancer* 1985 ; 56 : 972-7.
105. Jones SE. Non-Hodgkin's lymphomas. *JAMA* 1975 ;10 : 633-8.

106. Fram RJ, Skarin AR, Rosenthal DS. et al. Clinical, pathological and immunological features of patients with non-Hodgkin's lymphoma in a leukemic phase: a retrospective analysis of thirty-four patients. *Cancer* 1983 ; 52 : 1220-8.
107. Banfi A, Borandonna G, Ricci SB. et al. Malignant lymphomas of Waldeyer's ring: natural history and survival after radiotherapy. *Br Med J* 1972 ; 15 : 140-3.
108. Koziner B, Fillipa DA, Martelsman R. Characterization of malignant lymphomas in leukemic phase by multiple differentiation markers of mononuclear cells: correlation with clinical features and conventional morphology. *Am J Med* 1977 ; 63 : 556-67.
109. Carbone PP, Kaplan HS, Musshof K. Report of the committee in Hodgkin's disease staging classification. *Cancer Res* 1971 ; 31 : 1860-1.
110. Hermans J, Krol A.D.G., van Groningen K. et al. International prognostic index for aggressive non-Hodgkin's lymphomas is valid for all malignancies grade. *Blood* 1995 ; 86 : 1460-3.
111. Lopez-Guillermo A, Montserrat E, Bosch F. et al. Applicability of the international index for aggressive lymphomas to patients with low-grade lymphomas. *J Clin Oncol* 1994 ; 12 : 1343-8.
112. Taylor RE, Allan SG, McIntyre MA. et al. Influence of therapy on local control and survival in stage I and II intermediate and high grade non-Hodgkin's lymphoma. *Eur J Cancer Clin Oncol* 1988 ; 24 : 1771-7.
113. Connors JM, Klimo P, Faireji RN. et al. Brief chemotherapy and involved field radiation therapy for limited stage histologically aggressive lymphoma. *Ann Intern Med* 1987 ; 107 : 25-30.
114. Monfardini S, Banfi A, Bonnadonna G. et al. Improved five year survival after combined radiotherapy-chemotherapy for stage I-II non-Hodgkin's lymphoma. *Int J Radiat Oncol Biol Phys* 1980 ; 6 : 125-34.
115. Coltman CA, Dahlberg S, Jones SE. et al. CHOP is curative in thirty percent of patients with large cell lymphoma: a twelve year

- Southwest Oncology Group follow up, abstracted. Proc Am Soc Clin Oncol 1986 ; 5 : 197.
116. Canellos GP, Skarin AT, Klatt MM. et al. m-BACOD combination chemotherapy regimen in the treatment of diffuse large cell lymphoma. Semin Hematol 1987 ; 24 (suppl 1) : 2-7.
 117. Fisher R, DeVita V, Hubbard H. et al. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of ProMACE and MOPP chemotherapy. Ann Intern Med 1983 ; 98 : 304-9.
 118. Miller TP, Dahlberg S, Weick JK. et al. Unfavorable histologies of non-Hodgkin's lymphoma treated with Pro-MACE-CytaBOM: a groupwide Southwest Oncology Group Study. J Clin Oncol 1990 ; 8: 1951-8.
 119. Boyd DB, Coleman M, Papish SW. et al. COP-BLAM III infusional chemotherapy for diffuse large cell lymphoma. J Clin Oncol 1988 ; 6: 425-33.
 120. Sackett DL, Haynes RB, Guyatt GH, Tugwell P, eds. In Clinical Epidemiology A Basic Science for Clinical Medicine. Second Edition. Little Brown, Boston. 1991, p215-6.
 121. Phillips GL, Herzig RH, Lazarus MH. et al. Treatment of resistant malignant lymphoma with cyclophosphamide, total body irradiation and transplantation of cryopreserved autologous marrow. N Engl J Med 1984; 310 : 1557-61.
 122. Appelbaum FR, Sullivan KM, Buckner CD. et al. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation and marrow transplantation. J Clin Oncol 1987 ; 5 : 1340-7.
 123. Horning SJ, Negrin RS, Chao NJ. et al. Fractionated total body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 1994; 12 : 2552-8.
 124. Velaquez WS, Cabanillas F, Salvador P. et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose-Ara-C and dexamethasone (DHAP). Blood 1988 ; 71 : 117-22.

125. Rodriguez MA, Cabanillas FC, Hagemester FB. et al. A phase II trial of mesna/ifosfamide, mitoxantrone and etoposide for refractory lymphoma. *Ann Oncol* 1995 ; 6 : 609-13.
126. Philip T, Guglielmi C, Hagebeek A. et al. Autologous bone marrow transplantation as compared with salvage therapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. *N Engl J Med* 1995; 333 : 1540-5.
127. Marteli M, Vignetti M, Zinzani PL. et al. High-dose chemotherapy followed by autologous bone marrow transplantation versus dexamethasone, cisplatin and cytarabine in aggressive non-Hodgkin's lymphoma with partial response to front-line chemotherapy: a prospective randomized Italian multicenter study. *J Clin Oncol* 1996 ; 14 : 534-42.
128. Verdonck LF, Van Platten WLJ, Hagenbeek A. et al. Comparison of CHOP chemotherapy and autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. *N Engl J Med* 1995 ; 332 : 1045-51.
129. Vitolo U, Cortellazzo S, Liberati AM. et al. Intensified and high-dose chemotherapy with granulocyte-colony-stimulating factors and autologous stem cell transplantation support as first-line therapy in high-risk diffuse aggressive non-Hodgkin's lymphoma. *J Clin Oncol* 1997 ; 15 : 491-8.
130. Haioun C, Lepage E, Gisselbrecht C. et al. Comparison of autologous bone marrow transplantation and sequential chemotherapy for intermediate- grade and high-grade non-Hodgkin's lymphoma in first complete remission. A study of 464 patients. *J Clin Oncol* 1994; 12 : 2543-51.
131. Richman CM, Wiener RS, Yankee RA. Increase in circulating stem cells following chemotherapy in man. *Blood* 1976 ; 47 : 1031-9.
132. Schwartzberg L, Birch R, Blanco BR. et al. Rapid and sustained hematopoietic reconstitution by peripheral blood stem cell infusion

- alone following high-dose chemotherapy. Bone Marrow transplant 1993 ; 11 : 369-74.
133. Hass R, Ho AD, Bredthauer U. et al. Successful autologous transplantation of blood stem cell mobilized with recombinant human granulocyte-macrophage stimulating factor. Exp Hematol 1990 ; 18 : 94-8.
134. Pentengall R, Demuyneck H, Testa NG, Dexter TM. The engraftment capacity of peripheral blood stem cell mobilized chemotherapy +/- G-CSF. Int J Cell Clon 1992 ; 10(suppl) : 59-61.
135. Berenson RJ, Bensinger WL, Hill RS, et al. Engraftment after infusion of CD34+ marrow cells in patients with breast cancer or neuroblastoma. Blood 1991 ; 77 : 717-22.
136. Intragumtornchai T, Bullo C, Samattachai S. A cost-effectiveness analysis of up-front high-dose therapy and peripheral blood progenitor cell transplantation in Chulalongkorn Hospital. Presentation for Clinical Economics, MSc Course in Clinical Epidemiology. Siriraj Hospital, November 1994 .
137. Intragumtornchai T, Sutcharitchan P, Mahasandana S, Swasdikul D, Watananukul P. et al. Prognostic features of Thai patients with aggressive non-Hodgkin's lymphoma (abstract). Eight Congress Asian Pacific Division International Society of Hematology, Brisbane, Australia, 1995 :149.
138. Haioun C, Lepage E, Gisselbrecht C, et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor-risk aggressive non-Hodgkin's lymphoma: updated results of the prospective study LNH87-2. J Clin Oncol 1997 ; 15 : 1131-7.

APPENDIX A

ECOG CRITERIA FOR ESTIMATION OF PERFORMANCE STATUS

<u>Grade</u>	<u>Scale</u>
0	Fully Active, able to carry on pre-disease performance without restriction.
1	Ambulatory, but had symptoms.
2	Ambulatory, confined to bed and chair less than 50% of waking hours.
3	Capable of only limited self-care; confined to bed or chair more than 50% of waking hours.
4	Completely disabled. Cannot carry on any self-care. Totally confined to bed or chair.

สถาบันวิทยบริการ
จุฬาลงกรณ์มหาวิทยาลัย



VITAE

Dr. Tanin Intragumtornchai was born on March 22, 1955 in Bangkok, Thailand. He graduated from Faculty of Medicine, Chulalongkorn University in 1978 with a first degree honors for the degree of Doctor of Medicine. He had his internship training in Chulalongkorn Hospital in 1978 and earned the Diplomat for the Thai Board of Internal Medicine and Hematology in 1982 and 1984, respectively. In 1985-1986, he continued his hematology training at the Department of Hematology, University of Washington, USA.

Currently, Dr. Tanin Intragumtornchai is acting as an Associate Professor in the Division of Hematology, Department of Medicine, Faculty of Medicine, Chulalongkorn University. His main academic research is in the epidemiology of hematologic malignancies in Thailand as well as the treatment of patients with acute leukemias and lymphomas particularly using the high-dose therapy and hematopoietic stem cell transplantation. Presently, Dr. Tanin also holds the position of the Scientific Chairman of the Thai Society of Hematology.

สถาบันวิทยบริการ
จุฬาลงกรณ์มหาวิทยาลัย